In vivo antiestrogenic activity of mifepristone in the rat
Language English Country Italy Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
9211131
DOI
10.1007/bf03346908
Knihovny.cz E-resources
- MeSH
- Pituitary Gland, Anterior drug effects MeSH
- Estrogen Antagonists administration & dosage pharmacology MeSH
- Estradiol administration & dosage analogs & derivatives pharmacology MeSH
- Drug Combinations MeSH
- Injections, Subcutaneous MeSH
- Corticosterone blood MeSH
- Rats MeSH
- Mifepristone administration & dosage pharmacology MeSH
- Rats, Wistar MeSH
- Tamoxifen administration & dosage pharmacology MeSH
- Body Weight drug effects MeSH
- Organ Size drug effects MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Estrogen Antagonists MeSH
- estradiol 3-benzoate MeSH Browser
- Estradiol MeSH
- Drug Combinations MeSH
- Corticosterone MeSH
- Mifepristone MeSH
- Tamoxifen MeSH
The aim of this study was to find out whether mifepristone, known mainly as a substance with an antiprogesterone and antiglucocorticoid effect, also has an in vivo antiestrogenic activity on the adenohypophysis of the rat. Male Wistar rats were given chronically either estradiol-benzoate (EB, 1 mg s.c. twice a week) for a period of 12 days, or the non steroidal antiestrogen tamoxifen (1 mg/day/rat), or mifepristone (1 mg/day/rat), or EB together with mifepristone or tamoxifen. The hypertrophic effect of the EB on the weight of the adenohypophysis (AP) was significantly suppressed both by tamoxifen and by mifepristone. Mifepristone and tamoxifen reduced the increased content of PRL in the estrogenized adenohypophysis. Mifepristone but not tamoxifen significantly increased the content of the LH in the adenohypophysis of estrogen treated rats. Mifepristone and tamoxifen suppressed the increased concentration of cyclic nucleotides cAMP and cGMP in the estrogenized adenohypophysis. Mifepristone given alone increased serum levels of corticosterone, but when given together with EB deepened inhibiting effect EB on them. The results of our preliminary study show that mifepristone exerts a weak antiestrogenic activity on the level of hypophysis, however the pharmacology is not identical to tamoxifen.
See more in PubMed
J Pharmacol Exp Ther. 1987 May;241(2):401-6 PubMed
Biol Reprod. 1981 Mar;24(2):341-53 PubMed
J Clin Endocrinol Metab. 1994 Feb;78(2):440-8 PubMed
J Steroid Biochem Mol Biol. 1992 Jun;42(5):479-91 PubMed
Brain Res. 1996 Mar 11;712(1):148-52 PubMed
J Biol Chem. 1994 Apr 22;269(16):11945-9 PubMed
Endocrinology. 1993 Sep;133(3):1205-12 PubMed
Fertil Steril. 1989 Dec;52(6):1055-60 PubMed
J Endocrinol. 1990 Mar;124(3):425-32 PubMed
Biol Reprod. 1986 Dec;35(5):1154-61 PubMed
J Steroid Biochem Mol Biol. 1994 Mar;48(4):385-9 PubMed
Biol Reprod. 1988 Dec;39(5):1067-73 PubMed
Neuroendocrinology. 1985 Jan;40(1):72-7 PubMed
Am J Obstet Gynecol. 1987 Dec;157(6):1415-20 PubMed
J Neuroendocrinol. 1990 Aug 1;2(4):517-22 PubMed
Physiol Res. 1993;42(6):171-4 PubMed
Adv Cyclic Nucleotide Res. 1980;12:147-50 PubMed
Neuroendocrinology. 1993 Jun;57(6):1082-91 PubMed
J Endocrinol. 1992 Jan;132(1):115-22 PubMed
Life Sci. 1980 Mar 24;26(12):995-1005 PubMed
Physiol Res. 1992;41(4):279-84 PubMed
J Steroid Biochem Mol Biol. 1993 Apr;45(4):303-7 PubMed
Endocrinology. 1993 Dec;133(6):2418-23 PubMed
J Steroid Biochem. 1990 Aug 14;36(5):431-7 PubMed
